Payer-Negotiated Prices in the Diagnosis and Management of Cutaneous Melanoma in 2025
- 20 May 2026
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Oncology Practice
- p. OP2600048
Abstract
PURPOSE: The 2021 Federal Hospital Price Transparency Final Rule requires hospitals to publicly disclose payer-negotiated prices for services. Despite rising cutaneous melanoma incidence and strong association with geographic ultraviolet light exposure, price transparency for melanoma-specific care is incompletely understood. We assessed regional price compliance and variation among National Cancer Institute–designated Comprehensive Cancer Centers (NCI-CCCs) to inform clinician-patient cost discussions. METHODS: A cross-sectional analysis was conducted of private payer-specific negotiated prices in 2025 for 53 melanoma-related procedures using publicly available hospital price transparency files. Fifty-eight NCI-CCCs providing adult clinical care were included (data extracted January 1-March 31, 2025). Primary outcomes were markups relative to Medicare reimbursement and price dispersion across and within centers by billing code. Secondary outcomes included compliance with price transparency, markups, and price dispersion by US Census division. RESULTS: Overall, 47/58 centers (81.0%) were federally compliant, with lymph node procedures showing the highest median (IQR) markups relative to Medicare 7.9 (5.5-9.5). Diagnostic testing/imaging demonstrated the greatest price dispersion, with median (IQR) across-center and within-center ratios of 13.4 (9.5-16.6) and 11.2 (9.6-12.7), respectively. The Pacific division had the highest median price markups at 8.9 (3.7-13.4) and included five noncompliant centers. Across divisions, within- and across-center price dispersion were strongly correlated (ρ = 0.88; 95% CI, 0.53 to 1.00). CONCLUSION: The use of lymph node procedures, diagnostic testing, and imaging presents a key opportunity to mitigate financial toxicity for at-risk patients. Improved clinical accessibility of pricing data and policy intervention is still needed to advance patient-centered, value-driven care.Keywords
This publication has 41 references indexed in Scilit:
- Cutaneous MelanomaJAMA, 2025
- Drivers of Variation in Health Care Spending Across US CountiesJAMA Health Forum, 2025
- Changes in Health Care Costs, Survival, and Time Toxicity in the Era of Immunotherapy and Targeted Systemic Therapy for MelanomaJAMA Dermatology, 2023
- Cost-effectiveness of Response-Adapted De-escalation of Immunotherapy in Advanced MelanomaJAMA Dermatology, 2022
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040JAMA Dermatology, 2022
- Medical Service Use and Charges for Cancer Care in 2018 for Privately Insured Patients Younger Than 65 Years in the USJAMA Network Open, 2021
- Payer-Negotiated Prices in the Diagnosis and Management of Thyroid Cancer in 2021JAMA, 2021
- Comparison of Hospitals Affiliated With PPS-Exempt Cancer Centers, Other Hospitals Affiliated With NCI-Designated Cancer Centers, and Other Hospitals That Provide Cancer CareJAMA Internal Medicine, 2019
- Training Physicians to Provide High-Value, Cost-Conscious CareJAMA, 2015
- Association of UV Index, Latitude, and Melanoma Incidence in Nonwhite Populations—US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001Archives of Dermatology, 2005